Nature Biotechnology spoke to Rutter about building out the labs at UCSF, sequencing the hepatitis C virus and his short stint in the Navy.

Stan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.

Hosted on Acast. See acast.com/privacy for more information.

Stan Crooke is the founder, chairman and CEO of Isis Pharmaceuticals. Nature Biotechnology spoke with Crooke about his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader. For information regarding your data privacy, visit acast.com/privacy

Stan Crooke discusses his troubled youth, the crests and valleys of antisense, and the skills needed to be a good leader.

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.

Hosted on Acast. See acast.com/privacy for more information.

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens. For information regarding your data privacy, visit acast.com/privacy

Rachel King is president and CEO of GlycoMimetics and former chairwoman of the Biotechnology Innovation Organization. Talking with Nature Biotechnology, King discusses gene therapy, how a CEO handles layoffs and growing up with chickens.

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.

Hosted on Acast. See acast.com/privacy for more information.

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover. For information regarding your data privacy, visit acast.com/privacy

Colin Goddard is former CEO of OSI Pharmaceuticals, and current chairman and CEO of Coferon. His conversation with Nature Biotechnology details the history behind OSI's blockbuster drug Tarceva (erlotinib), the benefits of having a British accent in the United States and how to survive a hostile takeover.